Page 15 - Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

CUAJ – Consensus Statement Warren et al
Unresectable locally advanced and metastatic urothelial carcinoma

44. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally
advanced and metastatic urothelial carcinoma who have progressed following treatment
with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet
2016;387:1909-20.
45. Petrylak DP, Powles T, Bellmunt J, et al. Atezolizumab (MPDL3280A) monotherapy for
patients with metastatic urothelial cancer: Long-term outcomes from a phase 1 study.
JAMA Oncol 2018;4:537-44.
46. Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after
platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of
an open-label, phase 1 trial. Lancet Oncol 2018;19:51-64.
47. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients
with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-
randomised, open-label, phase 1b study. Lancet Oncol 2017;18:212-20.
48. Di Nunno V, De Luca E, Buttigliero C, et al. Immune-checkpoint inhibitors in previously
treated patients with advanced or metastatic urothelial carcinoma : A systematic review
and meta-analysis. Crit Rev Oncol / Hematol 2018;129:124-32.
49. Lavoie J-M, Black PC, Eigl BJ. Predictive biomarkers for checkpoint blockade in
urothelial cancer: A systemic review. J Urol 2019;136:Epub ahead of print Feb 4.
50. FDA.gov: U.S. Food and Drug Administration. https://www.fda.gov/. Accessed April 10,
2019.
51. Canada.ca. Health Canada. https://www.canada.ca/en/health-canada.html. Accessed
February 20, 2019.
52. EMA.Europa.ed. European Medicines Agency. https://www.ema.europa.eu/. Accessed
February 20, 2019.
53. NCCN.org. NCCN: National Comprehensive Cancer Network Practice Network. Practice
Guidelines in Oncology Bladder version 1.2019 – Dec 20, 2018. https://www.nccn.org.
Accessed February 21, 2019.
54. CADTH.ca: pan Canadian Oncology Drug Review. https://cadth.ca/pcodr. Accessed
February 20, 2019.
55. Edge S, Byrd D, Compton C, (editors). AJCC cancer staging
manual. https://www.springer.com/gp/book/9780387884424. Published 2010.
56. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant
chemotherapy in invasive bladder cancer : a systematic review and meta-analysis. Lancet
2003;361:1927-34.
57. James N, Hussain S, Hall E,et al. Radiotherapy with or without chemotherapy in muscle-
invasive bladder cancer. N Engl J Med 2012;366:1477-88.
58. Zargar-Shoshtari K, Zargar H, Lotan Y, et al. A multi-institutional analysis of outcomes of
patients with clinically node positive urothelial bladder cancer treated with induction
chemotherapy and radical cystectomy. J Urol 2016;195:53-59.
59. Abufaraj M, Dalbagni G, Daneshand S, et al. The role of surgery in metastatic bladder
cancer: A systematic review. Eur Urol 2018;73:543-57.
60. Nieuwenhuijzen JA, Bex A, Meinhardt W, et al. Neoadjuvant methotrexate, vinblastine,
doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J
Urol 2005;174:80-84.